MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Method for Preparing Higly Optically Active 2-Sufonyloxy-1-Phenylethanol Derivatives

Korea Health Industry Development Institute
more effective methods for preparing 2-sufonyloxy-1-phenylethanol derivatives in a high yield and a high e.e. value are now required in the industries of pharmacy

Mechanism of action

□ Efficient Method for Preparing Optically Active 2-Sulfonyloxy-1-Phenylethanol derivatives, □ High e.e.(enantiomeric exess) Value of Product ,□ Strong IP Position , □ Safe Process.

Full description

Technology Platform

The core technology of Dr. Kee-In, Lee and Dr. Do-Min, Lee  is to provide novel method for preparing higly optically active 2-sulfonyloxy-1-phenylethanol derivatives of formula 1 by using a rhodium compoud catalyst.  Rhodium compound of formula 2 or 3 reduce α-sulfonyloxy acetophenone compound asymetrically in a high e.e. value.

                                                      

Background and unmet needs: Opticlly active 2-sulfonyloxy-1-phenylethanol derivatives of formula 1 are essential intermediate for producing 2-amino-1-phenylethanol derivatives which have been used in the preparations of several agricultural chemicals, medical supplies, fine chemicals and building blocks, and 60 biologically active substances. The asymmetric reduction of α-substituted acetophenone using oxazaborolidine catalyst and borane is mainly employed method in the preparation of 2-sulfonyloxy-1-phenylethanol derivatives. However, such method require high cost due to the use of expensive catalyst in an excess amount, and have wide fluctuation of the optical activity of the product depending on the substitution of the phenyl moiety, in addition, the reduction is highly sensitive to humidity.

Overall Reaction Scheme of Preparing 2-sulfonyloxy-1-phenylethanol derivatives : Generally, the compound of formula1 is prepared by conventional method using acetophenon as starting material and α-mesyloxy acetophenone as essential intermediate.  

 

Wherein, X is a halogen atom such as -Cl and –Br, or a leaving group such as mesyloxy (-OMs) and tosyloxy          (-OTs) ; R is one or more substituents, each independently, selected from the group of H, F, Cl, Br, OMe, OBn, NO2, CF3, Me, tert-Bu, CH2OMe (Me=methyl, Bn=benzyl, Bu= Butyl).

The α-sulfonyloxy acetophenone compound used in the above process may be prepared by a conventional method ; for instance, the α-tosyloxy acetophenone compound may be prepared by reacting acetophenone with [hydroxyl(tosyloxy)iodido] benzene and similary, the α-mesyloxy acetophenone compound may be prepared by reacting acetophenone with [hydroxyl(mesyloxy)iodido] benzene.

Rhodium compound of formula 2 or 3 reduce α-acetophenone compound asymetrically to produce optically active 2-sulfonyloxy-1-phenylethanol derivatives.

 

Preparation of the rhodium catalyst of formula 2 and 3

the rhodium catalyst can be obtained in a yield of 70% by reacting 1 equivalent of (pentamethylcyclopentadienyl) rhodium(III) chloride dimer ([Rh(C5Me5)Cl2J2), 2 equivalent of optically active l,2-diphenylethylene-N-(p-toluenesulfonyl)diamine (TsDPEN) and 4 equivalent of triethylamine in methylene chloride, and washing and recrystallizing the reaction mixture. Not only by the conventional methods above, the rhodium catalyst of formula 2 and 3 may be prepared by methods (A) and (B) described below.

Method (A) - reacting 1 equivalent of (pentamethylcyclopentadienyl)rhodium(lll) chloride dimer, 2 equivalent of optically active 1,2-diphenylethylene-N-(p-toluenesulfonyl)diamine(TsDPEN) and 4 equivalent of triethylamine in methylene chloide as a solvent to obtain a reaction mixture, and removing the solvent from the reaction mixture ; and

Method (B) – reacting 1 equivalent of (pentamethylcyclopentadienyl)rhodium(lll) chloride dimer and 2 equivalent of optically active 1,2-diphenylethylene-N-(p-toluenesulfonyl)diamine(TsDPEN) in methylene chloide as a solvent, in the absence of triethylamine, to obtain a reaction mixture, and removing the solvent from the reaction mixture.

The compound of formula 2 and 3 can be easily and efficiently prepared by the method (A) and (B) in a higher yield than that of conventional method, and therefore, the compound of formula 1 obtained in the asymmetrical reduction of α- chloro acetophenones using the catalyst of formula 2 or 3 exhibits a higher e.e. value than that of the products obtained in the conventional methods.

 

Development status

Early Stage

Patent information

 

Country

Status

Patent, Publication or Appln. No.

PCT

-

WO 2008/054155

Korea

Granted

10-0821567

 

Type of business relationship sought

development collaboration, or non-exclusive or exclusive licensing agreement

Company details

Korea Health Industry Development Institute

KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us